Immuno-Oncology Application of Humanized Immune System (HIS) Mice Supporting Human Myeloid and Lymphoid Cells - Part II in a three-part series
Since the development of the super immunodeficient CIEA NOG mouse® in the early 2000s enabled improved humanized immune system (HIS) mice, HIS models have been widely adopted in immuno-oncology research. Because HIS mice can support both tumor cell line xenografts (CDX) or patient-derived xenografts (PDX) in addition to relevant human immune cells, they are widely used in the preclinical evaluation of immune-modulating therapeutics. While foundational HIS models primarily supported lymphoid cells, second-generation host strains expressing human cytokines made HIS models with human innate and adaptive cells possible. While researchers can now study immune-modulating therapeutics in the context of interactions between human myeloid and lymphoid lineages, HIS mouse engraftment profiles are host strain-specific and can be influenced by the engraftment protocol and donor variability.
This webinar will discuss humanization of the NOG-EXL and hIL-6 NOG host strains, which both support a range of human cell types including myeloid and lymphoid lineages, along with considerations for successful efficacy evaluation of IO therapies in HIS models. This webinar is part two of a three-part series - click here to explore this educational series.
Watch this webinar to:
- Gain a general understanding of humanized immune system mouse models that can support both innate and adaptive human immune cells
- Learn about differences between super immunodeficient mouse models and how engraftment strategies can influence immune cell populations
- Understand how to select the best humanized immune system model based on your needs for specific cell populations
- How to apply HIS models to cutting-edge immuno-oncology questions
Dr. Laura Griffin
Field Applications Scientist
Dr. Laura Griffin has been working with preclinical models for a decade and is experienced in choosing appropriate models for various research applications. She obtained her PhD in Food Science and Technology at Virginia Tech where she focused on the mechanisms by which dietary bioactive compounds influence the onset of metabolic syndrome using preclinical models. As a postdoctoral fellow at the Plants for Human Health Institute, her research shifted to focus on the impact of the gut microbiome on metabolism of bioactive compounds. In addition to her expertise in metabolic diseases in preclinical models, Dr. Griffin is also versed in laboratory animal diets and their usage in preclinical applications.